MCID: ULC005
MIFTS: 25

Ulcer of Lower Limbs

Categories: Skin diseases

Aliases & Classifications for Ulcer of Lower Limbs

MalaCards integrated aliases for Ulcer of Lower Limbs:

Name: Ulcer of Lower Limbs 39 12 15
Ulcer of Heel and Midfoot 12
Ulcer of Lower Limb 17
Ulcer of Ankle 12
Ulcer of Thigh 12
Ulcer of Calf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8529
ICD10 34 L97

Summaries for Ulcer of Lower Limbs

Disease Ontology : 12 Ulcer of lower limbs is a chronic ulcer of skin where the ulcer is not a decubitus ulcer.

MalaCards based summary : Ulcer of Lower Limbs, also known as ulcer of heel and midfoot, is related to peripheral vascular disease. An important gene associated with Ulcer of Lower Limbs is CCL5 (C-C Motif Chemokine Ligand 5). The drugs Saxagliptin and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone marrow and testes.

Related Diseases for Ulcer of Lower Limbs

Diseases related to Ulcer of Lower Limbs via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 9.8

Symptoms & Phenotypes for Ulcer of Lower Limbs

Drugs & Therapeutics for Ulcer of Lower Limbs

Drugs for Ulcer of Lower Limbs (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saxagliptin Approved Phase 4 361442-04-8 11243969
2
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
3
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
4
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
5
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
6
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
7
Tazobactam Approved Phase 4,Phase 3 89786-04-9 123630
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
9
Metronidazole Approved Phase 4 443-48-1 4173
10
Piperacillin Approved Phase 4,Phase 3 66258-76-2 43672
11
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
12
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 85721-33-1 2764
13
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
14
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
15
Petrolatum Approved, Investigational Phase 4,Phase 2,Not Applicable 8009-03-8
16
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
17
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
18
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
19
Fusidic Acid Approved, Investigational Phase 4,Early Phase 1 6990-06-3 3000226
20
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
21
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
22
Cefoxitin Approved Phase 4 35607-66-0 441199
23
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
24
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
25
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
26
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
27
Sulbactam Approved Phase 4 68373-14-8
28
Sultamicillin Approved, Investigational Phase 4 76497-13-7
29
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
30
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
31
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
32
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
33
Coal tar Approved Phase 4,Phase 1,Phase 2,Not Applicable 8007-45-2
34
Polidocanol Approved Phase 4 9002-92-0
35
Daptomycin Approved, Investigational Phase 4,Phase 3 103060-53-3 16129629
36
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430 439542
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
38
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
39
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
40 Octenidine Investigational Phase 4,Not Applicable 71251-02-0
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
42 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 Antitubercular Agents Phase 4,Phase 3,Not Applicable
45 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
46 Hormone Antagonists Phase 4,Phase 3,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Not Applicable
48 Hormones Phase 4,Phase 3,Not Applicable
49
protease inhibitors Phase 4,Phase 3,Not Applicable,Early Phase 1
50 Incretins Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 827)
# Name Status NCT ID Phase Drugs
1 A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf® Unknown status NCT02011724 Phase 4
2 Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics Unknown status NCT01418456 Phase 4 antibiotics
3 Juxta-CuresTM Versus Bandaging for Venous Ulcers Unknown status NCT02790593 Phase 4
4 Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers Unknown status NCT02816749 Phase 4
5 Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers Unknown status NCT02742233 Phase 4 saxagliptin;placebo
6 A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers. Unknown status NCT02344329 Phase 4
7 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
8 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
9 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
10 Physiotulle vs Urgotul in the Treatment of Leg Ulcer Completed NCT01238419 Phase 4
11 Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras Completed NCT02104180 Phase 4
12 To Assess Analgesia Provided by Continuous Sciatic Nerve Block in Patients With Hypertensive Leg Ulcer Completed NCT01964911 Phase 4 Ropivacaïne
13 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
14 A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers Completed NCT00235209 Phase 4
15 Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers Completed NCT01036438 Phase 4
16 A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers Completed NCT01743053 Phase 4
17 Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel Completed NCT01153633 Phase 4
18 A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers Completed NCT01327937 Phase 4
19 Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers. Completed NCT01449422 Phase 4
20 Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers Completed NCT00521027 Phase 4
21 Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers Completed NCT00953186 Phase 4
22 Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers Completed NCT00638872 Phase 4 Polydeoxyribonucleotide
23 Wound Fluid Protease Levels During Use of Novel Wound Dressing Completed NCT01567150 Phase 4
24 Neuromuscular Electrical Therapy in Venous Ulcers Completed NCT01372020 Phase 4
25 Skin Ulcers Treatment With an Handicraft Topical Device Completed NCT02512159 Phase 4
26 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
27 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
28 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
29 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
30 LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers Completed NCT02224742 Phase 4
31 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
32 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
33 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
34 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
35 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
36 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
37 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy
38 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
39 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
40 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
41 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes Completed NCT01472432 Phase 4 Placebo;vildagliptin
42 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
43 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
44 Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers Completed NCT00235196 Phase 4
45 Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot Completed NCT00224796 Phase 4
46 Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed NCT00044746 Phase 4 Piperacillin/Tazobactam
47 GrafixPL PRIME Evaluation Case Study Recruiting NCT03742440 Phase 4
48 Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
49 A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers Recruiting NCT02799121 Phase 4
50 Evaluation of Woulgan in Diabetic Foot Ulcer Recruiting NCT02631512 Phase 4

Search NIH Clinical Center for Ulcer of Lower Limbs

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcer of Lower Limbs cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Ulcer of Lower Limbs:
Peripheral blood-derived hematopoietic stem cells for leg gangrene
Embryonic/Adult Cultured Cells Related to Ulcer of Lower Limbs:
Peripheral blood-derived hematopoietic stem cells

Genetic Tests for Ulcer of Lower Limbs

Anatomical Context for Ulcer of Lower Limbs

MalaCards organs/tissues related to Ulcer of Lower Limbs:

42
Skin, Bone Marrow, Testes, Endothelial, Colon, Spinal Cord, T Cells

Publications for Ulcer of Lower Limbs

Articles related to Ulcer of Lower Limbs:

# Title Authors Year
1
Therapy with autologous adipose-derived regenerative cells for the care of chronic ulcer of lower limbs in patients with peripheral arterial disease. ( 23773718 )
2013
2
[The value of regulated upon activation normal T cell expressed and secreted in the pathogenesis of varicose ulcer of lower limbs]. ( 19953896 )
2009

Variations for Ulcer of Lower Limbs

Expression for Ulcer of Lower Limbs

Search GEO for disease gene expression data for Ulcer of Lower Limbs.

Pathways for Ulcer of Lower Limbs

GO Terms for Ulcer of Lower Limbs

Sources for Ulcer of Lower Limbs

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....